Skip to main content
رجوع
Watch Compare

Cue Biopharma, Inc.

جودة البيانات: 100%
CUE
NASDAQ Manufacturing Chemicals
KWD 0.44
▼ KWD 0.03 (-7.26%)
6 months return
—
Momentum
Neutral
5Y revenue growth
16.44%

النمو

Revenue Growth (5Y)
16.44%
أعلى من متوسط القطاع (1.82%)
Revenue (1Y)195.75%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-169.41%
أقل من متوسط القطاع (-54.49%)
ROIC-111.66%
Net Margin-96.85%
Op. Margin-96.67%

الأمان

Debt / Equity
N/A
Current Ratio1.66
Interest Coverage-265.52

التقييم

PE (TTM)
-1.05
أعلى من متوسط القطاع (-1.50)
P/B Ratio2.10
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Revenue grew 16.44% annually over 5 years — strong growth
Negative free cash flow of -21.86 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 179.31%
Capital efficient — spends only 0.64% of revenue on capex

Price History

الاتجاهات المالية

السعر المستهدف للمحللين

محلل 1
Buy
+813.2%
upside to target
الحالي
KWD 0.44
Consensus Target
KWD 4.00
KWD 4.00
أدنى
KWD 4.00
أعلى
التوقعات
ربحية السهم المستقبلية
-KWD 0.60
الإيرادات المقدّرة
1.00 M

مفاجآت الأرباح

EPS
Reported Estimate Forecast
Next: Q2 2026 · Rev Est: 0.0
Q12025 Q22025 Q32025 Q42025 Q2 '26
Reported -KWD 0.17 -KWD 0.09 -KWD 0.07 KWD 0.01 —
Estimate -KWD 0.15 -KWD 0.13 -KWD 0.09 -KWD 0.09 —
المفاجأة -10.87% +30.77% +17.65% +111.11% —

Growth

Rev 5Y: 16.44% · Earnings 1Y: N/A
Revenue Growth (1Y) 195.75% Revenue Growth (3Y) 123.67%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 16.44% Earnings Growth (5Y) N/A

Profitability

ROE: -169.41% · Net Margin: -96.85%
Revenue (TTM) 27.47 M Net Income (TTM) -26.60 M
ROE -169.41% ROA -73.54%
Gross Margin N/A Operating Margin -96.67%
Net Margin -96.85% Free Cash Flow (TTM) -21.86 M
ROIC -111.66% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 1.66
Debt / Equity N/A Current Ratio 1.66
Interest Coverage -265.52 Asset Turnover 0.76
Working Capital 10.30 M Tangible Book Value 13.25 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -1.05 · EV/EBITDA: N/A
P/E Ratio -1.05 Forward P/E N/A
P/B Ratio 2.10 P/S Ratio 1.02
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 27.88 Fwd Earnings Yield N/A
FCF Yield -78.42%
Market Cap 27.88 M Enterprise Value 16.18 M

Per Share

EPS: -0.28 · FCF/Share: -0.22
EPS (Diluted TTM) -0.28 Revenue / Share 0.28
FCF / Share -0.22 OCF / Share -0.22
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 82.19% · CapEx/Rev: 0.64%
CapEx / Revenue 0.64% FCF Conversion 82.19%
SBC-Adj. FCF -27.58 M Growth Momentum 179.31

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 27.47 M 9.29 M 5.49 M 1.25 M 14.94 M
Net Income -26.60 M -40.67 M -50.73 M -53.01 M -44.16 M
EPS (Diluted) -0.28 -0.72 -1.11 -1.49 —
Gross Profit — — — — —
Operating Income -26.55 M -41.50 M -52.15 M -53.22 M -43.71 M
EBITDA — — — — —
R&D Expenses 37.74 M 36.30 M 40.80 M 38.58 M 41.35 M
SG&A Expenses — — — — —
D&A 958,000.0 397,000.0 556,000.0 922,216.0 1.26 M
Interest Expense 100,000.0 100,000.0 130,000.0 -713,815.0 —
Income Tax 500,000.0 400,000.0 — 0.0 495,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 42.21 M 32.19 M 61.53 M 91.28 M 83.40 M
Total Liabilities 15.78 M 14.69 M 24.45 M 25.60 M 17.91 M
Shareholders' Equity 26.43 M 17.50 M 37.09 M 65.68 M 65.49 M
Total Debt — 37,000.0 4.04 M 8.07 M —
Cash & Equivalents 27.14 M 22.46 M 48.51 M 51.61 M 64.37 M
Current Assets 36.98 M 25.14 M 51.45 M 77.19 M 68.47 M
Current Liabilities 13.49 M 13.69 M 17.08 M 11.55 M 12.79 M

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1605 نظير)
المقياس السهم وسيط القطاع
P/E -1.1 -1.5
P/B 2.1 1.6
ROE % -169.4 -54.5
Net Margin % -96.9 -41.5
Rev Growth 5Y % 16.4 1.8
D/E — 0.3